Pharmacotherapy of Inflammatory and Pruritic Manifestations of Corticosteroid-Responsive Dermatoses Focus on Clobetasol Propionate.
Clobetasol-17 propionate is a dihalogenated corticosteroid which, on the basis of the vasoconstrictor assay, is classified as the most potent of all topical steroids. Since 1973 it has been marketed specifically for the short term topical treatment of moderate and severe cortico-responsive dermatose...
| Publicado en: | Clinical Medicine Insights: Therapeutics no. 2; pp. 523 - 538 |
|---|---|
| Autores principales: | , , , |
| Formato: | Journal Article |
| Publicado: |
Sage Publications Inc.
2010
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=70639041&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 70639041 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1179559X B3KY jtl: Clinical Medicine Insights: Therapeutics issn: 1179559X maglogo: Y pubinfo: dt: 2010 iid: 2 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 70639041 104989440 10.4137/CMT.S1993 70639041 ppf: 523 ppct: 15 formats: fmt: @attributes: type: P tig: atl: Pharmacotherapy of Inflammatory and Pruritic Manifestations of Corticosteroid-Responsive Dermatoses Focus on Clobetasol Propionate. aug: au: Zampetti, Anna Feliciani, Claudio Tulli, Antonello Amerio, Pierluigi affil: Department of Dermatology Università Cattolica del Sacro Cuore, Rome, Italy sug: ab: Clobetasol-17 propionate is a dihalogenated corticosteroid which, on the basis of the vasoconstrictor assay, is classified as the most potent of all topical steroids. Since 1973 it has been marketed specifically for the short term topical treatment of moderate and severe cortico-responsive dermatoses for its antinflammatory, immunosuppressive and antimitotic effects. Psoriasis, atopic dermatitis, chronic eczema, boullous disorders and itching dermatosis of the genital area are usually well controlled by clobetasol with a great improvement of quality of life in patients. In this manuscript, we reviewed data concerning pharmacology, efficacy and safety profile of clobetasol-17 proprionate, updated studies on its use, efficacy of different formulations and impact on quality of life in corticosteroid-responsive dermatoses. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|